Nutriband Inc. (NASDAQ: NTRB) has achieved a significant milestone with the successful completion of commercial manufacturing and scale-up for its AVERSA Fentanyl abuse-deterrent transdermal patch, leading to a revised price target of $15 by Noble Capital Markets. This development, as highlighted by Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, represents a pivotal moment for Nutriband, enabling the company to move forward with clinical supplies production and an Investigational New Drug (IND) application for a Phase 1 trial.
The AVERSA program, utilizing the 505(b)(2) regulatory pathway, is designed to demonstrate the patch's reduced appeal to recreational drug users, a step considered low risk by analysts. With the FY2027 EPS forecast adjusted to $1.57, Nutriband's adherence to its projected timeline and the avoidance of an anticipated Q1 2025 equity raise have been key factors in this optimistic outlook. Sales are projected to commence in FY2027, with the New Drug Application (NDA) submission expected between late 2025 and early 2026.
This advancement in Nutriband's AVERSA technology not only underscores the company's progress in developing abuse-deterrent pharmaceutical products but also highlights the potential impact on addressing the opioid crisis by reducing the misuse and diversion of fentanyl, a potent synthetic opioid. For more details on the report, visit https://ibn.fm/IWkz5.
